Clinical Research Institute HUCH
Sponsored, fully signed Clinical Trial Agreements (except grants)

HYKS-INSTITUUTTI

Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)
January		x				x
January	x		NightstaRx Ltd	A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)	Head and Neck Center	
February	x		Kyowa Kirin International	X-Linked Hypophosphatemia Registry	Children and Adolescents	
February	x		Essential Medical Inc.	Post-Market Clinical Registry to Evaluate the Safety and Performance of MANTA Vascular Closure Device Under Real World Conditions in the European Union	Heart and Lung Center	
February	x					x
March		x				x
March	x		Chordate Medical AB	A clinical investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the treatment of Non Allergic Rhinitis (KOSNAR)	Head and Neck Center	
March	X		Santen	Ciclosporin 1 mg/ml eye drop emulsion (Ikervis ®) for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes: Clinical effectivness, tolerability and safety in a real world setting.	HUCH Head and Neck Center	
March	x					x
March	x		Alnylam Pharmaceuticals Inc.	ALN-ASI-003 A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias	Internal Medicine and Rehabilitation	
April	x					x

Clinical Research Institute HUCH
Sponsored, fully signed Clinical Trial Agreements (except grants)

HYKS-INSTITUUTTI

Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)
May		x	Oulu Univeristy	Assessment of brain dysfunction in intensive care patients by analyzing propofol-induced EEG changes	Perioperative, Intensive Care an Pain Medicine	
May	x					x
May		x	Aarhus University Hospital/Institute of Clinical Medicine Aarhus University Hospital	NOR-GRASPALL – Single-Arm PK/PD and safety study of GRASPA for patients with hypersensitivity to PEG-Asparaginase, diagnosed with Ph(-) Acute Lymphoblastic Leukemia	Children and Adolescents	
May	x		Bristol-Myers Squibb	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma	Comprehensive Cancer Center	
May	x		Deciphera Pharmaceuticals, LLC	A Phase 3, InterVentional, Double-Blind, Placebo Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with Advanced Gastrointestinal Stromal Tumors who have Received Treatment with Prior Anticancer Therapies	Comprehensive Cancer Center	
May	x		Novo Nordisk Farma Oy	Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity	Abdominal Center	
June	x		F Hoffmann-La Roche Limited	A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer Immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy	Comprehensive Cancer Center	

Clinical Research Institute HUCH
Sponsored, fully signed Clinical Trial Agreements (except grants)

HYKS-INSTITUUTTI

Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)
June	x		F Hoffmann-La Roche Limited	A phase III, randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolzumab plus chemotherapy for patients with early relapsing recurrent (inoperable locally advanced or metastatic) triple-negative breast cancer	Comprehensive Cancer Center	

Clinical Research Institute HUCH
Sponsored, fully signed Clinical Trial Agreements (except grants)

HYKS-INSTITUUTTI

Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)

Clinical Research Institute HUCH
Sponsored, fully signed Clinical Trial Agreements (except grants)

HYKS-INSTITUUTTI

Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)

Clinical Research Institute HUCH
Sponsored, fully signed Clinical Trial Agreements (except grants)

HYKS-INSTITUUTTI

Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)

Clinical Research Institute HUCH
Sponsored, fully signed Clinical Trial Agreements (except grants)

HYKS-INSTITUUTTI

Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)

Clinical Research Institute HUCH
Sponsored, fully signed Clinical Trial Agreements (except grants)

HYKS-INSTITUUTTI

Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)